Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana M Tari

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 30, 2005
Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cellsAna M Tari, Ann-Marie Simeone, Yu-Jiang Li, et al.
The Journal of Biological Chemistry|March 20, 2003
Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoterSangeeta K Cheema, Sandip K Mishra, Vivek M Rangnekar, et al.
International Journal of Oncology|January 29, 2011
JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cellsVanity McMurtry, Joseph E Saavedra, René Nieves-Alicea, et al.
Cancer Research|February 20, 2004
Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cellsAnn-Marie Simeone, Yu-Jiang Li, Lyle D Broemeling, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 18, 2002
Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulatesFouad Brahimi, Stephanie L Matheson, Fabienne Dudouit, et al.
Carcinogenesis|February 8, 2005
N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cellsAnn-Marie Simeone, Chu-Xia Deng, Gary J Kelloff, et al.
Biochemical Pharmacology|June 29, 2005
Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potencyFouad Brahimi, Zakaria Rachid, James P McNamee, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 2004
The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivoStephanie L Matheson, James P McNamee, Taiqui Wang, et al.
International Journal of Cancer|September 24, 2004
Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNAFouad Brahimi, Zakaria Rachid, Qiyu Qiu, et al.
The Journal of Biological Chemistry|April 18, 2003
The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibitionXiao-Feng Le, Francois-Xavier Claret, Amy Lammayot, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 30, 2005
Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cellsAna M Tari, Ann-Marie Simeone, Yu-Jiang Li, et al.
The Journal of Biological Chemistry|March 20, 2003
Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoterSangeeta K Cheema, Sandip K Mishra, Vivek M Rangnekar, et al.
International Journal of Oncology|January 29, 2011
JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cellsVanity McMurtry, Joseph E Saavedra, René Nieves-Alicea, et al.
Cancer Research|February 20, 2004
Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cellsAnn-Marie Simeone, Yu-Jiang Li, Lyle D Broemeling, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 18, 2002
Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulatesFouad Brahimi, Stephanie L Matheson, Fabienne Dudouit, et al.
Carcinogenesis|February 8, 2005
N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cellsAnn-Marie Simeone, Chu-Xia Deng, Gary J Kelloff, et al.
Biochemical Pharmacology|June 29, 2005
Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potencyFouad Brahimi, Zakaria Rachid, James P McNamee, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 2004
The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivoStephanie L Matheson, James P McNamee, Taiqui Wang, et al.
International Journal of Cancer|September 24, 2004
Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNAFouad Brahimi, Zakaria Rachid, Qiyu Qiu, et al.
The Journal of Biological Chemistry|April 18, 2003
The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibitionXiao-Feng Le, Francois-Xavier Claret, Amy Lammayot, et al.
Pageof 4